BioXcel Therapeutics, Inc. (BTAI)
Largest Insider Buys in Sector
BTAI Stock Price History Chart
BTAI Stock Performance
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Insider Activity of BioXcel Therapeutics, Inc.
Over the last 12 months, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $455,502 worth of BioXcel Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $34.4M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,108 shares for transaction amount of $14,514 was made by MUELLER PETER (director) on 2019‑08‑23.
List of Insider Buy and Sell Transactions, BioXcel Therapeutics, Inc.
| 2024-10-03 | Sale | Chief Scientific Officer | 7,175 0.0181% | $0.55 | $3,946 | +3.08% | ||
| 2024-10-03 | Sale | See Remarks | 6,863 0.0173% | $0.55 | $3,775 | +3.08% | ||
| 2024-10-03 | Sale | Chief Financial Officer | 7,175 0.0181% | $0.55 | $3,946 | +3.08% | ||
| 2024-10-03 | Sale | See Remarks | 5,556 0.014% | $0.55 | $3,056 | +3.08% | ||
| 2024-10-03 | Sale | Chief Commercial Officer | 6,272 0.0158% | $0.55 | $3,450 | +3.08% | ||
| 2024-09-16 | Sale | CEO and President | 1,982 0.0052% | $0.69 | $1,367 | -11.02% | ||
| 2024-09-16 | Sale | Chief Scientific Officer | 355 0.0009% | $0.69 | $245 | -11.02% | ||
| 2024-09-16 | Sale | See Remarks | 345 0.0009% | $0.69 | $238 | -11.02% | ||
| 2024-09-16 | Sale | Chief Financial Officer | 356 0.0009% | $0.69 | $246 | -11.02% | ||
| 2024-09-16 | Sale | Chief Commercial Officer | 215 0.0006% | $0.69 | $149 | -11.02% | ||
| 2024-09-16 | Sale | See Remarks | 138 0.0004% | $0.69 | $95 | -11.02% | ||
| 2024-06-17 | Sale | CEO and President | 2,134 0.0051% | $1.28 | $2,739 | -52.24% | ||
| 2024-06-17 | Sale | Chief Scientific Officer | 372 0.0009% | $1.28 | $476 | -52.24% | ||
| 2024-06-17 | Sale | See Remarks | 361 0.0008% | $1.26 | $456 | -52.24% | ||
| 2024-06-17 | Sale | Chief Financial Officer | 372 0.0009% | $1.26 | $470 | -52.24% | ||
| 2024-06-17 | Sale | See Remarks | 155 0.0004% | $1.28 | $199 | -52.24% | ||
| 2024-06-17 | Sale | Chief Commercial Officer | 244 0.0006% | $1.26 | $308 | -52.24% | ||
| 2024-06-05 | Sale | CEO and President | 409,136 0.3263% | $0.49 | $199,619 | -59.94% | ||
| 2024-06-04 | Sale | CEO and President | 1.02M 0.3359% | $0.20 | $205,516 | -60.21% | ||
| 2024-04-04 | Sale | CEO and President | 5,268 0.0153% | $2.62 | $13,823 | -65.96% |
Insider Historical Profitability
| Mehta Vimal | CEO and President | 51666 0.1069% | $0.49 | 9 | 11 | +91.12% |
| Yocca Frank | Chief Scientific Officer | 28278 0.0585% | $0.49 | 5 | 9 | +91.88% |
| Rodriguez Javier | See Remarks | 23770 0.0492% | $0.49 | 0 | 6 | |
| Steinhart Richard I | Chief Financial Officer | 20279 0.0419% | $0.49 | 3 | 7 | +87.62% |
| O'Neill Vincent | See Remarks | 19601 0.0405% | $0.49 | 0 | 9 | |
| Wiley Matthew T. | Chief Commercial Officer | 19011 0.0393% | $0.49 | 0 | 4 | |
| BioXcel LLC | 10 percent owner | 8546750 17.6774% | $0.49 | 0 | 1 | |
| BioXcel Holdings, Inc. | 10 percent owner | 8546750 17.6774% | $0.49 | 0 | 1 | |
| MUELLER PETER | director | 168320 0.3481% | $0.49 | 6 | 0 | +104.84% |
| Nandabalan Krishnan | 0 0% | $0.49 | 1 | 5 | +93.45% |
Institutional Investor Ownership
| Fidelity Investments | $7.03M | 6.65 | 2.49M | -0.97% | -$68,943.36 | <0.0001 | |
| BlackRock | $3.75M | 3.54 | 1.33M | -3.36% | -$130,137.36 | <0.0001 | |
| The Vanguard Group | $3.1M | 2.93 | 1.1M | +0.91% | +$27,951.83 | <0.0001 | |
| Ameriprise Financial | $1.63M | 1.54 | 579,164 | +7.04% | +$107,442.03 | <0.0001 | |
| State Street | $1.31M | 1.24 | 464,908 | +5.58% | +$69,304.34 | <0.0001 | |
| Geode Capital Management | $1.29M | 1.22 | 457,920 | +1.71% | +$21,696.77 | <0.0001 | |
| Armistice Capital Llc | $1.05M | 0.99 | 370,973 | New | +$1.05M | <0.01 | |
| Beacon Pointe Advisors Llc | $850,893.00 | 0.8 | 301,735 | 0% | +$0 | 0.01 | |
| Morgan Stanley | $626,883.00 | 0.59 | 222,299 | +15.93% | +$86,136.88 | <0.0001 | |
| Northern Trust | $596,717.00 | 0.56 | 211,602 | -6.12% | -$38,879.30 | <0.0001 | |
| Charles Schwab | $538,535.00 | 0.51 | 190,970 | +1.84% | +$9,757.19 | <0.0001 | |
| UBS | $414,983.00 | 0.39 | 147,157 | +204.55% | +$278,720.52 | <0.0001 | |
| BNY Mellon | $347,077.00 | 0.33 | 123,077 | -2.71% | -$9,669.78 | <0.0001 | |
| Wells Fargo | $347,103.00 | 0.33 | 123,086 | +58.15% | +$127,624.92 | <0.0001 | |
| Castleview Partners LLC | $274,326.00 | 0.26 | 97,279 | New | +$274,326.00 | 0.18 | |
| Susquehanna International Group | $254,336.00 | 0.24 | 90,190 | New | +$254,336.00 | <0.0001 | |
| Pennant Capital Management Llc | $236,598.00 | 0.22 | 83,900 | 0% | +$0 | 0.04 | |
| Tocqueville Asset Management | $136,065.00 | 0.13 | 48,250 | -3.98% | -$5,640.00 | <0.01 | |
| Federated Hermes | $135,098.00 | 0.13 | 47,907 | New | +$135,098.00 | <0.0001 | |
| Bank of America | $133,578.00 | 0.13 | 47,368 | -54.6% | -$160,630.31 | <0.0001 | |
| Millennium Management LLC | $127,250.00 | 0.12 | 45,124 | -48.69% | -$120,772.44 | <0.0001 | |
| Bank of Montreal | $120,008.00 | 0.11 | 42,108 | -5.38% | -$6,817.21 | <0.0001 | |
| Citadel Advisors LLC | $114,613.00 | 0.11 | 40,643 | +662.53% | +$99,582.43 | <0.0001 | |
| Thrivent Financial For Lutherans | $113,000.00 | 0.11 | 40,000 | 0% | +$0 | <0.0001 | |
| Cambridge Investment Research Advisors Inc | $107,000.00 | 0.1 | 38,050 | 0% | +$0 | <0.0001 | |
| Davenport & Company | $96,966.00 | 0.09 | 34,385 | -2.83% | -$2,820.01 | <0.01 | |
| Xtx Topco Ltd | $88,018.00 | 0.08 | 31,212 | New | +$88,018.00 | <0.01 | |
| AllianceBernstein | $84,572.00 | 0.08 | 29,990 | 0% | +$0 | <0.0001 | |
| Atom Investors Lp | $84,081.00 | 0.08 | 29,816 | New | +$84,081.00 | 0.01 | |
| RhumbLine Advisers | $83,703.00 | 0.08 | 29,685 | +2.42% | +$1,976.62 | <0.0001 | |
| Renaissance Technologies | $67,000.00 | 0.06 | 23,707 | New | +$67,000.00 | <0.0001 | |
| Goldman Sachs | $64,211.00 | 0.06 | 22,770 | +18.59% | +$10,067.34 | <0.0001 | |
| Invesco | $53,131.00 | 0.05 | 18,841 | +33.14% | +$13,225.65 | <0.0001 | |
| Raymond James Associates | $52,257.00 | 0.05 | 18,531 | -2.21% | -$1,178.75 | <0.0001 | |
| U.S. Bancorp | $50,853.00 | 0.05 | 18,033 | 0% | +$0 | <0.0001 | |
| Capital Investment Advisory Services Llc | $50,267.00 | 0.05 | 17,825 | 0% | +$0 | 0.01 | |
| Deutsche Bank | $49,454.00 | 0.05 | 17,537 | 0% | +$0 | <0.0001 | |
| SeaCrest Investment Management, LLC | $48,645.00 | 0.05 | 17,250 | -4.96% | -$2,538.00 | 0.01 | |
| Barclays | $41,000.00 | 0.04 | 14,772 | -47.04% | -$36,423.17 | <0.0001 | |
| Simplex Trading Llc | $40,000.00 | 0.04 | 14,321 | New | +$40,000.00 | <0.01 | |
| Virtu Financial Llc | $39,000.00 | 0.04 | 13,990 | -76.49% | -$126,907.51 | <0.01 | |
| Creative Planning | $37,292.00 | 0.04 | 13,224 | -34.61% | -$19,740.17 | <0.0001 | |
| BB&T | $30,679.00 | 0.03 | 10,879 | 0% | +$0 | <0.0001 | |
| Apollon Wealth Management, LLC | $28,679.00 | 0.03 | 10,170 | -3.48% | -$1,034.93 | <0.01 | |
| American International Group | $29,088.00 | 0.03 | 10,315 | +2.3% | +$654.23 | <0.0001 | |
| JPMorgan Chase | $25,199.00 | 0.02 | 8,936 | -29.65% | -$10,622.72 | <0.0001 | |
| Zurich Cantonal Bank | $21,550.00 | 0.02 | 7,642 | -3.19% | -$710.63 | <0.0001 | |
| Tower Research Capital | $13,048.00 | 0.01 | 4,627 | -66.55% | -$25,957.82 | <0.0001 | |
| AllSquare Wealth Management, LLC | $12,766.00 | 0.01 | 4,527 | 0% | +$0 | 0.01 | |
| Citigroup | $9,912.00 | 0.01 | 3,515 | +21.63% | +$1,762.45 | <0.0001 |